SCHEMBL14616813

SCHEMBL14616813

COCCn1c(-c2cnc(-c3ccc4scnc4c3)[nH]2)nc2c(N3CCCC3)nccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 3/20 0.41
▸ RPS6KA5 O75582 1/20 0.35
▸ KCNH2 Q12809 1/20 0.32
▸ DYRK2 Q92630 3/20 0.32
▸ CCNA2 P20248 1/20 0.31
▸ CDK2 P24941 1/20 0.31
▸ TTK P33981 1/20 0.31
▸ LCK P06239 2/20 0.31
▸ KDR P35968 2/20 0.31
▸ TGFBR1 P36897 2/20 0.31
▸ KDM1A O60341 1/20 0.31
▸ HTR6 P50406 1/20 0.31
▸ CASR P41180 1/20 0.31
▸ PTGER4 P35408 1/20 0.31
▸ MAP3K11 Q16584 1/20 0.31
▸ DRD2 P14416 1/20 0.31
▸ DRD3 P35462 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ GLA P06280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14616824 0.99 RIPK2 (0.40) RIPK2RPS6KA5KCNH2DYRK2CCNA2
SCHEMBL14616812 0.98 RIPK2 (0.41) RIPK2RPS6KA5KCNH2DYRK2KDM1A
SCHEMBL14616825 0.95 RIPK2 (0.40) RIPK2KCNH2DYRK2TTKMAP3K11
SCHEMBL14616807 0.93 RIPK2 (0.40) RIPK2TTKALDH1A1TSHR
SCHEMBL14616826 0.90 RIPK2 (0.38) RIPK2KDM1ADRD2DRD3
SCHEMBL14616811 0.88 TTK (0.38) RIPK2TTKCNR2
SCHEMBL2552056 0.86 RPS6KA5 (0.35) RIPK2RPS6KA5KCNH2DYRK2CCNA2
SCHEMBL14616809 0.86 RIPK2 (0.37) RIPK2
SCHEMBL14616808 0.86 RIPK2 (0.37) RIPK2
SCHEMBL2546139 0.85 RPS6KA5 (0.34) RIPK2RPS6KA5KCNH2DYRK2CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 RIPK2 255/4885RPS6KA5 153/4885KCNH2 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback